MSH2 and cancer: Genetic testing in V-3 identified a heterozygous MSH2 mutation without biallelic mutations or CMMRD symptoms (e.g., early cancers, café-au-lait spots) (Wimmer and Kratz, 2010; Wimmer et al., 2014).